AstraZeneca plc’s (AZN) Neutral Rating Reaffirmed at BNP Paribas
BNP Paribas reissued their neutral rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Friday morning. BNP Paribas currently has a GBX 5,200 ($67.88) price objective on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on the stock. Shore Capital reiterated a hold rating on shares of AstraZeneca plc in a research note on Wednesday, September 28th. Deutsche Bank AG reiterated a buy rating and set a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research note on Wednesday, September 28th. Citigroup Inc. reiterated a buy rating on shares of AstraZeneca plc in a research note on Friday, September 23rd. Jefferies Group reiterated a buy rating and set a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a research note on Wednesday, September 21st. Finally, Societe Generale reiterated a buy rating and set a GBX 7,000 ($91.37) price target on shares of AstraZeneca plc in a research note on Wednesday, September 14th. Five research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. AstraZeneca plc presently has a consensus rating of Hold and an average target price of GBX 4,926.80 ($64.31).
Shares of AstraZeneca plc (LON:AZN) opened at 5034.00 on Friday. The stock has a 50 day moving average of GBX 5,015.00 and a 200 day moving average of GBX 4,398.79. The firm’s market cap is GBX 63.68 billion. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00.
The business also recently declared a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were paid a GBX 68.70 ($0.90) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a dividend yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.